The use of Buserelin-depo in the treatment ofcombined pathology of reproductive organs
Khashukoeva A.Z., Agaeva M.I., Savchenko T.N., Agaeva Z.A., Burdenko M.V., Lobacheva Yu.I.
The article presents the current data on the use of gonadotropin-releasing hormone (GnRH) agonists in the therapy of combined proliferative diseases of reproductive organs. This pathology is detected in most cases in patients aged 40–45 years. The main clinical symptoms of proliferative diseases include pain and abnormal uterine bleeding. Timely diagnosis of proliferative nosologies is very challenging due to the variety of symptoms, conflicting theories of etiopathogenesis, and difficulties in differential diagnosis. GnRH agonists completely block the synthesis of sex hormones, marked antiproliferative and antiangiogenic effects; therefore, they are the first line therapy for combined proliferative diseases demonstrating high efficacy and relative safety. The analysis of the literature showed high efficacy of the Russian drug Buserelin-depo in the treatment of combined proliferative gynecologic diseases (it is administered 3.75 mg intramuscularly, once every 28 days, during 6 months of therapy and 3 months of preoperative preparation). The use of Buserelin-depo makes it possible to reduce the size of myomatous nodes by 52% of the original volume, to control pain syndrome and abnormal uterine bleeding, to reduce the risk of recurrence of hyperplastic processes of the endometrium, and to reduce the risk of intraoperative complications. This enables the clinicians to use it widely not only in the therapy of proliferative diseases, but also in the preparation of patients with uterine fibroids and endometriosis for surgical treatment and postoperative adjuvant therapy. Its use can significantly improve the quality of life of this cohort of patients, reduce the number of radical treatment methods and improve the outcomes of organ-preserving operations.
Conclusion: GnRH agonists are the first line therapy for combined proliferative pathology of reproductive organs due to their effect on all links of pathogenesis, demonstrating high efficacy and safety. The Bucerelin-depo medication is highly effective and affordable; it has a convenient scheme of administration, which ensures high adherence to treatment; the use of algorithms for complex management is interesting and promising.
Authors’ contributions: Khashukoeva A.Z., Agaeva M.I., Savchenko T.N., Agaeva Z.A., Burdenko M.V., Lobacheva Yu.I. – developing the concept and design of the study, obtaining the data for analysis, reviewing publications on the subject of the article, writing the manuscript.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Khashukoeva A.Z., Agaeva M.I., Savchenko T.N., Agaeva Z.A., Burdenko M.V., Lobacheva Yu.I.
The use of Buserelin-depo in the treatment ofcombined pathology of reproductive organs.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (8): 170-174 (in Russian)
https://dx.doi.org/10.18565/aig.2024.180
Keywords
Bucerelin-depo
endometriosis
uterine myoma
endometrial hyperplasia
References
- Савельева Г.М., Сухих Г.Т., Серов В.Н, Радзинский В.Е., Манухин И.Б., ред. Национальное руководство. Гинекология. М.: ГЭОТАР-Медиа; 2022. 1008 с. [Savelyeva G.M., Sukhikh G.T., Serov V.N, Radzinsky V.E., Manukhin I.B., ed. National Guide. Gynecology. Moscow: GEOTAR-Media; 2022. 1008 p. (in Russian)].
- Bofill Rodriguez M., Lethaby A., Low C., Cameron I.T. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2019; 8(8): CD001016. https://dx.doi.org/10.1002/14651858.CD001016.pub3.
- Becker C.M., Bokor A., Heikinheimo O., Horne A., Jansen F., Kiesel L. et al.; ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum. Reprod. Open. 2022; 2022(2): hoac009. https://dx.doi.org/10.1093/hropen/hoac009.
- Barra F., Grandi G., Tantari M., Scala C., Facchinetti F., Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin. Biol. Ther. 2019; 19(4): 343-60. https://dx.doi.org/10.1080/14712598.2019.1581761.
- Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020; 76(1): 151-6. https://dx.doi.org/10.1111/his.13977.
- Vercellini P., Bandini V., Buggio L., Barbara G., Berlanda N., Dridi D. et al. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? Hum. Reprod. Open. 2023; 2023(2): hoad008. https://dx.doi.org/10.1093/hropen/hoad008.
- Resta C., Moustogiannis A., Chatzinikita E., Ntalianis D.M., Ntalianis K.M., Philippou A. et al. Gonadotropin-releasing hormone (GnRH)/GnRH receptors and their role in the treatment of endometriosis. Cureus. 2023; 15(4): e38136. https://dx.doi.org/10.7759/cureus.38136.
- Surrey E.S. GnRH agonists in the treatment of symptomatic endometriosis: a review. F S Rep. 2022; 4(2 Suppl): 40-5. https://dx.doi.org/10.1016/j.xfre.2022.11.009.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Миома матки. 2020. 48 с. [Ministry of Health of the Russian Federation. Clinical guidelines. Uterine fibroids. 2020. 48 p. (in Russian)].
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2022. 42 c. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. 2022. 42 p. (in Russian)].
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometrial hyperplasia. 2024. (in Russian)].
- Довлетханова Э.Р., Абакарова П.Р., Межевитинова Е.А. Аналоги гонадотропин-рилизинг-гормона в лечении миомы матки. Акушерство и гинекология. 2024; 3: 172-8. [Dovletkhanova E.R., Abakarova P.R., Mezhevitinova E.A. Analogues of gonadotropin-releasing hormone in the treatment of women with uterine fibroids. Obstetrics and Gynecology. 2024; (3): 172-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.266.
- Оразов М.Р., Хамошина М.Б., Муллина И.А., Артеменко Ю.С. Гиперплазия эндометрия – от патогенеза к эффективной терапии. Акушерство и гинекология: новости, мнения, обучение. 2021; 9(3): 21-8. [Orazov M.R., Khamoshina M.B., Mullina I.A., Artemenko Yu.S. Endometrial hyperplasia – from pathogenesis to effective therapy. Obstetrics and Gynecology: News, Opinions, Training. 2021; 9(3): 21-8. (in Russian)]. https://dx.doi.org/10.33029/2303-9698-2021-9-3-21-28.
- Gong L., Zhang S., Han Y., Long Q., Zou S., Cao Y. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial. J. Clin. Pharmacol. 2015; 55(8): 848-53. https://dx.doi.org/10.1002/jcph.485.
- Адамян Л.В., Арсланян К.Н., Харченко Э.И., Логинова О.Н. Современные направления в медикаментозном лечении эндометриоза. Проблемы репродукции. 2019; 25(6): 58-66. [Adamyan L.V., Arslanyan K.N., Kharchenko E.I., Loginova O.N. Modern trends in the treatment of endometriosis. Russian Journal of Human Reproduction. 2019; 25(6): 58-66. (in Russian)]. https://dx.doi.org/10.17116/repro20192506158.
- Рухляда Н.Н., Бирюкова Е.И. Особенности фармакокинетики и биологические эффекты агонистов гонадотропин-рилизинг-гормона. Акушерство и гинекология. 2023; 2: 154-8. [Rukhlyada N.N., Biryukova E.I. The characteristics of pharmacokinetics and the biological effects of gonadotropin-releasing hormone agonists. Obstetrics and Gynecology. 2023; (2): 154-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.42.
- Рухляда Н.Н. Эффективность режима назначения Бусерелина-депо с пролонгированным межинъекционным интервалом: гормональный профиль и приемлемость лечения пациенток с эндометриозом. Акушерство и гинекология. 2023; 10: 153-8. [Rukhliada N.N. The effectiveness of the administration regimen of Buserelin-depo with a prolonged interval between injections: hormonal profile and acceptability of treatment for patients with endometriosis. Obstetrics and Gynecology. 2023; (10): 153-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.245.
- Пустотина О.А. Агонисты гонадотропин-рилизинг гормона и add-back терапия. Российский вестник акушера-гинеколога. 2023; 23(2): 63-9. [Pustotina OA. Agonists of gonadotropin-releasing-hormone and add-back-therapy. Russian Bulletin of Obstetrician-Gynecologist. 2023; 23(2): 63-9. (in Russian)]. https://dx.doi.org/10.17116/rosakush20232302163.
- Zhang K., Huang S., Xu H., Zhang J., Wang E., Li Y. et al. Effectiveness of gonadotrophin-releasing hormone agonist therapy to improve the outcomes of intrauterine insemination in patients suffering from stage I-II endometriosis. Ann. Med. 2022; 54(1): 1330-8. https://dx.doi.org/10.1080/07853890.2022.2071458.
- Yang Y., Zhu W., Chen S., Zhang G., Chen M., Zhuang Y. Laparoscopic Surgery Combined with GnRH agonist in endometriosis. J. Coll. Physicians Surg. Pak. 2019; 29(4): 313-6. https://dx.doi.org/10.29271/jcpsp.2019.04.313.
- Zhang Y., Sun L., Guo Y., Cheng J., Wang Y., Fan S. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet. Gynecol. Surv. 2014; 69(2): 100-8. https://dx.doi.org/10.1097/OGX.0000000000000036.
Received 29.07.2024
Accepted 05.08.2024
About the Authors
Asiyat Z. Khashukoeva, Dr. Med. Sci., Professor, Professor at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(916)340-38-13, azk@mail.ru, https://orcid.org/0000-0001-7591-6280Madina I. Agaeva, PhD, Teaching Assistant at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(926)081-81-70, madlen1690@mail.ru, https://orcid.org/0000-0001-5138-8357
Zoya A. Agaeva, Dr. Med. Sci., Professor, Senior Lecturer at the Department of Ultrasound and Functional Research Method, N.V. Sklifosovsky Research Institute of Emergency Medicine, 129090, Russia, Moscow, B. Sukharevskaya sqr., 3, +7(952)822-56-56, zoya466@mail.ru, https://orcid.org/0000-0002-2205-0880
Tatyana N. Savchenko, Dr. Med. Sci., Professor, Professor at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(968)478-36-76, 12111944t@mail.ru, https://orcid.org/0000-0001-7244-4944
Marina V. Burdenko, PhD, Associate Professor at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, bmv-0306@rambler.ru, https://orcid.org/0000-0002-0304-4901
Yulia I. Lobacheva, Teaching Assistant at the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University,
Ministry of Health of Russia, 117997, Russia, Moscow, Ostrovityanov str., 1, +7(917)509-08-50, mitu.10@mail.ru, https://orcid.org/0009-0007-9652-3568
Similar Articles
